Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd
301130
Company Profile
Business description
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd is mainly engaged in the research, development, production, and sales of chemical APIs and preparations. It is focused on the development and manufacturing of iron supplement preparations, circulatory disorder treatment drugs, anti-psychotic drugs, and APIs. The company's product portfolio comprises Compound Ferrous Sulfate Folic Acid Tablets, Risperidone Orally Disintegrating Tablets, Escitalopram Oxalate Tablets, Daphne Capsules, Zoledronic Acid for Injection, etc., and various APIs.
Contact
No. 777, Xidian Street
Panshi Economic Development Zone
Jilin Province
Panshi132300
CHNT: +86 43265888277
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
313
Stocks News & Analysis
stocks
AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event
We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.
stocks
The most popular ASX trades in FY26
A closer look at the stocks and ETFs that captured Aussie investors’ attention in FY26.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,018.10 | 41.40 | -0.46% |
| CAC 40 | 8,299.09 | 138.80 | -1.64% |
| DAX 40 | 24,763.12 | 392.29 | -1.56% |
| Dow JONES (US) | 51,711.65 | 506.93 | -0.97% |
| FTSE 100 | 10,639.17 | 77.80 | -0.73% |
| HKSE | 25,210.81 | 318.15 | 1.28% |
| NASDAQ | 25,137.69 | 553.21 | -2.15% |
| Nikkei 225 | 66,422.60 | 307.00 | 0.46% |
| NZX 50 Index | 13,795.31 | 0.00 | 0.00% |
| S&P 500 | 7,408.30 | 90.66 | -1.21% |
| S&P/ASX 200 | 8,839.00 | 38.60 | -0.43% |
| SSE Composite Index | 3,876.78 | 9.74 | 0.25% |